Reviewing Spectral AI (MDAI) & Its Competitors

Spectral AI (NASDAQ:MDAI) is one of 159 public companies in the “Medical Devices” industry, but how does it weigh in compared to its peers? We will compare Spectral AI to related companies based on the strength of its profitability, analyst recommendations, valuation, risk, earnings, dividends and institutional ownership.

Volatility and Risk

Spectral AI has a beta of 0.56, meaning that its stock price is 44% less volatile than the S&P 500. Comparatively, Spectral AI’s peers have a beta of 0.88, meaning that their average stock price is 12% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Spectral AI and its peers, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spectral AI	0	0	3	1	3.25
Spectral AI Competitors	381	1543	2174	102	2.48

Spectral AI presently has a consensus price target of $4.50, suggesting a potential upside of 248.84%. As a group, “Medical Devices” companies have a potential upside of 199.29%. Given Spectral AI’s stronger consensus rating and higher probable upside, analysts plainly believe Spectral AI is more favorable than its peers.

Profitability

This table compares Spectral AI and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Spectral AI	-89.85%	N/A	-104.64%
Spectral AI Competitors	-299.42%	-147.81%	-24.18%

Valuation & Earnings

This table compares Spectral AI and its peers gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Spectral AI	$22.53 million	-$20.85 million	-0.96
Spectral AI Competitors	$895.60 million	$66.42 million	102.71

Spectral AI’s peers have higher revenue and earnings than Spectral AI. Spectral AI is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Institutional & Insider Ownership

67.1% of Spectral AI shares are owned by institutional investors. Comparatively, 31.6% of shares of all “Medical Devices” companies are owned by institutional investors. 56.7% of Spectral AI shares are owned by company insiders. Comparatively, 24.7% of shares of all “Medical Devices” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Spectral AI beats its peers on 8 of the 13 factors compared.

About Spectral AI

Spectral AI, Inc., an artificial intelligence (AI) company, focuses on developing predictive medical diagnostics in the United States. The company develops medical diagnostics for faster and accurate treatment decisions in wound care with applications involving patients with burns and diabetic foot ulcers. Its products include DeepView System, a predictive analytics platform integrated with the predictive AI-Burn, which combines AI algorithms and multispectral imaging (MSI) imaging for an assessment of wound healing potential and offers clinicians an objective and immediate assessment of a wound’s healing potential prior to treatment or other medical intervention; and DeepView SnapShot M, a handheld, portable, and wireless diagnostic tool, that provides a potential enhanced and expanded use for the government and emergency care, first responders, and potentially home health care professionals. The company is headquartered in Dallas, Texas.